Transport of paclitaxel (taxol) across the blood-brain barrier in vitro and in vivo

Journal of Clinical Investigation

Volumn 110, Issue 9, 2002, Pages 1309-1318

  Fellner, Stephan ^a   Bauer, Björn ^a   Miller, David S ^a   Schaffrik, Martina ^a   Fankhänel, Martina ^a   Spruß, Thilo ^a   Bernhardt, Günther ^a   Graeff, Claudia ^a   Färber, Lothar ^a   Gschaidmeier, Harald ^a   Buschauer, Armin ^a   Fricker, Gert ^a  

^a Inst Pharmazeut Technol/Biopharm   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN DERIVATIVE; GLYCOPROTEIN P; LEUKOTRIENE C4; MULTIDRUG RESISTANCE PROTEIN 2; PACLITAXEL; SODIUM CYANIDE; VALSPODAR;

ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN LEVEL; CANCER CELL; CANCER TRANSPLANTATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG PENETRATION; DRUG RELEASE; DRUG TISSUE LEVEL; DRUG TRANSPORT; ENDOTHELIUM CELL; FEMALE; FLUORESCENCE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LIVER LEVEL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SWINE; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING;

EID: 0036841686     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0215451     Document Type: Article

References (53)

1. Kroger, N., Achterrath, W., Hegewisch-Becker, S., Mross, K., and Zander, A.R. 1999. Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat. Rev. 25:279-291.
2. Nathan, F.E., Berd, D., Sato, T., and Mastrangelo, M.J. 2000. Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma. Cancer. 88:79-87.
3. Muggia, F.M., et al. 2000. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study. J. Clin. Oncol. 18:106-115.
4. Papadimitriou, C.A. 2000. Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: Long-term results of a phase II study. Cancer. 89:1547-1554.
5. Belani, C.P. 2000. Paclitaxel and docetaxel combinations in non-small cell lung cancer. Chest. 117(Suppl 1):144S-151S.
6. Bunn, P.A. Jr., and Kelly, K. 2000. New combinations in the treatment of lung cancer: A time for optimism. Chest 117(Suppl 1):138S-143S.
7. Lee, J.S., et al. 1997. Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: A preliminary report. Sem. Oncol. 24(4 Suppl. 12):S12/52-S12/55.
8. Glantz, M.J., Chamberlain, M.C., Chang, S.M., Prados, M.D., and Cole, B.F. 1999. The role of paclitaxel in the treatment of primary and metastatic brain tumors. Sem. Rad. Oncol. 9:27-33.
9. Brandes, A.A., Pasetto, L.M., and Monfardini, S. 2000. New drugs in recurrent high grade gliomas. Anticancer Res. 20:1913-1920.
10. Eiseman, J.L., et al. 1994. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother. Pharmacol. 34:465-471.
11. Heimans, J.J., et al. 1994. Paclitaxel (taxol) concentrations in brain tumor tissue. Ann. Oncol. 5:951-953.
12. Sparreboom, A., et al. 1997. Limited oral bioavailability and active epithelial excretion of paclitaxel (taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA. 94:2031-2035.
13. van Asperen, J., et al. 1997. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Brit. J. Cancer. 76:1181-1183.
14. Martin, C., et al. 2000. Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol. 58:624-632.
15. Beaulieu, E., Demeule, M., Ghitescu, L., and Beliveau, R. 1997. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem. J. 326:539-544.
16. Miller, D.S., Nobmann, S., Gutmann, H., Drewe, J., and Fricker, G. 2000. Xenobiotic transport in isolated brain microvessels studied by confocal microscopy. Mol. Pharmacol. 58:1357-1367.
17. Seetharaman, S., Barrand, M.A., Maskell, L., and Scheper, R.J. 1998. Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates. J. Neurochem. 70:1151-1159.
18. Nobmann, S., Bauer, B., and Fricker, G. 2001. Ivermectin excretion by isolated functionally intact brain endothelial capillaries. Brit. J. Pharmacol. 132:722-728.
19. Ohnishi, T., et al. 1995. In vivo and in vitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier. Biochem. Pharmacol. 49:1541-1544.
20. Huwyler, J., Drewe, J., Kluseman, C., and Fricker, G. 1996. Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium. Brit. J. Pharmacol. 118:1879-1885.
21. Drewe, J., et al. 1999. HIV protease inhibitor ritonavir: A more potent inhibitor of p-glycoprotein than the cyclo-sporine analogue SDZ PSC-833. Biochem. Pharmacol. 57:1147-1152.
22. Schinkel, A.H., et al. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:491-502.
23. Mayer, A., et al. 1997. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest. 100:2430-2436.
24. Miller, D.S., and Pritchard, J.B. 1991. Indirect coupling of organic anion secretion to sodium in teleost (Paralichthys lethostigma) renal tubules. Am. J. Physiol. 261:R1470-R1477.
25. Schramm, U., Fricker, G., Wenger, R., and Miller, D.S. 1995. p-Glycoprotein mediated transport of a fluorescent cyclosporin analogue in teleost proximal tubules. Am. J. Physiol. 268:F46-F52.
26. Gutmann, H., et al. 1999. Modulation of MRP expression in porcine brain capillary endothelial cells in vitro. Drug Metab. Dispos. 27:937-941.
27. Audus, K. L., and Borchardt, R.T. 1986. Characterization of an in vitro blood-brain barrier model system for studying drug transport and metabolism. Pharm. Res. 3:81-87.
28. Bernhardt, G., Reile, H., Birnböck, H., Spruss, T., and Schönenberger, H. 1992. Standardized kinetic microassay to quantify differential chemosensitivity based on proliferative activity. Cancer Res. Clin. Oncol. 118:35-43.
29. Reile, H., Birnböck, H., Bernhardt, G., Spruss, T., and Schönenberger, H. 1990. Computerized determination of growth kinetic curves and doubling times from cells in microculture. Anal. Biochem. 187:262-267.
30. Spruss, T., Schlemmer, R., Bernhardt, G., Wiesenmeyer, F., and Baumann, O. 1996. Five-year breeding data, immunology, and tumor take rates of an NMRI nude mouse colony. In Immunodeficient Animals: Models for Cancer Research. Volume 51. W. Arnold, P. Köpf-Maier, B. Michael, editors. 145-150.
31. Sparreboom, A., van Tellingen, O., Nooijen, W.J., and Beijnen, J.H. 1995. Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography. J. Chromatogr. B. 664:383-391.
32. Fellner, S., et al. 2000. The MDR modulator SDZ PSC 833 increases paclitaxel concentrations in the brain of nude mice. Arch. Pharm. Pharm. Med. Chem. 333(Suppl. 2):42. (Abstr.)
33. Romeis, B. 1989. Mikroskopische Technik. P. Böck, editor. Urban & Schwarzenberg. Munich, Germany. 497-499.
34. Cordon-Cardo, C. 1991. Immunhistochemical analysis of p-glycoprotein expression in normal and tumor tissues in humans. In Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. Plenum Press. New York, New York, USA. 310-315.
35. Fricker, G., Gutmann, H., Droulle, A., Drewe, J., and Miller, D.S. 1999. Epithelial transport of anthelmintic ivermectin in a novel model of isolated proximal kidney tubules. Pharm. Res. 16:1570-1575.
36. Fracasso, P.M., et al. 1995. Phase I trial of paclitaxel (taxol) and SDZ PSC 833 in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 14:486a. (Abstr.)
37. Fracasso, P.M., et al. 2000. Phase I study of paclitaxel in combination with a multi drug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. J. Clin. Oncol. 18:1124-1134.
38. Goldstein, L.J. 1996. MDR1 gene expression in solid tumors. Eur. J. Cancer 32A:1039-1050.
39. Oda, Y., et al. 1997. Expression of MDR1/p-glycoprotein and multidrug resistance-associated protein in childhood solid tumours. Virchows Arch. 430:99-105.
40. Abe, T., et al. 1998. Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. J. Neurooncol. 40:11-18.
41. von Bossanyi, P., Diete, S., Dietzmann, K., Warich-Kirches, M., and Kirches, E. 1997. Immunhistochemical expression of p-glycoprotein and gluthathione S-transferase in cerebral gliomas and response to chemotherapy. Acta Neuropathol. (Berl.). 94:605-611.
42. Scheper, R.J., et al. 1988. Monoclonal antibody jsb-1 detects a highly conserved epitope on the p-glycoprotein associated with multi-drug-resistance. Int. J. Cancer. 42:389-394.
43. Henson, J.W., Cordon-Catdo, C., and Posner, J.B. 1992. P-glycoprotein expression in brain tumors. J. Neurooncol. 14:37-43.
44. Toth, K., Vaughan, M.M., Peress, N.S., Slocum, H.K., and Rustum, Y.M. 1996. MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am. J. Pathol. 149:853-858.
45. Sawada, T., Kato, Y., Sakayori, N., Takekawa, Y., and Kobayashi, M. 1999. Expression of multidrug-resistance P-glycoprotein (Pgp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors. Brain Tumor Pathol. 16:23-27.
46. Schaffrik, M. 2000. Untersuchungen zur Multi-Drug-Resistenz Orthotoper Menschlicher Hirntumoren in der Nacktmaus: Expression und Funktionalität des P-Glykoproteins 170. Diploma thesis. University of Regensburg, Regensburg, Germany.
47. Altenschöpfer, P. 1998. Tumorpharmakologische und Analytische Untersuchungen zur Optimierung neuer Zytostatika-Beladener Bioabbaubarer Implantate für die Interstitielle Chemotherapie Maligner Hirntumoren. Ph.D. thesis. University of Regensburg, Regensburg, Germany.
48. Altenschöpfer, P., Spruss, T., Bernhardt, G., and Buschauer, A. Comparison of subcutaneously and orthotopically implanted glioblastomas. Paper presented at: International Symposium: Relevance of Tumor Models for Anticancer Drug Development; October 15-17, 1997; Freiburg, Germany. (Abstr.)
49. Kreis, W., Budman, D.R., and Calabro, A. 2001. A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents. Cancer Chemother. Pharmacol. 47:78-82.
50. Arnold, S.M., and Patchell, R.A. 2001. Diagnosis and management of brain metastases. Hematol. Oncol. Clin. North Am. 15:1085-1107.
51. Zhang, Y., Han, H., Elmquist, W.F., and Miller, D.W. 2000. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res. 876:148-153.
52. van Asperen, et al. 1996. Altered pharmacokinetics of vinblastine in MDR1a P-glycoprotein-deficient mice. J. Natl. Cancer Inst. 88:994-999.
53. Drion, N., Lemaire, M., Lefauconnier, J.M., and Scherrmann, J.M. 1996. Role of P-glyco-protein in the blood-brain transport of colchicine and vinblastine. J. Neurochem. 67:1688-1693.